Tudor Investment Corp ET AL Takes Position in Amneal Pharmaceuticals, Inc. $AMRX

Tudor Investment Corp ET AL purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 92,010 shares of the company’s stock, valued at approximately $921,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackBarn Capital Partners LP increased its holdings in Amneal Pharmaceuticals by 19.6% during the 2nd quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock worth $27,883,000 after purchasing an additional 564,916 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Amneal Pharmaceuticals by 22.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,332,366 shares of the company’s stock valued at $10,779,000 after buying an additional 240,676 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Amneal Pharmaceuticals by 1,440.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock worth $11,790,000 after buying an additional 1,062,045 shares in the last quarter. AustralianSuper Pty Ltd acquired a new stake in shares of Amneal Pharmaceuticals during the third quarter worth approximately $3,238,000. Finally, Walleye Capital LLC increased its stake in shares of Amneal Pharmaceuticals by 26.9% in the second quarter. Walleye Capital LLC now owns 708,946 shares of the company’s stock worth $5,735,000 after buying an additional 150,104 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ AMRX opened at $11.95 on Tuesday. The company has a market capitalization of $3.76 billion, a price-to-earnings ratio of 51.96 and a beta of 1.34. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $15.42. The business has a 50 day simple moving average of $13.56 and a 200-day simple moving average of $12.20.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Barclays began coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target on the stock. Truist Financial boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $14.20.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.